TRANSDERMAL PATCH-BASED DELIVERY OF TIRZEPATIDE: A CONTROLLED RELEASE STRATEGY FOR DIABETES TREATMENT
DOI:
https://doi.org/10.22159/ijms.2025v13i4.55051Keywords:
Transdermal Patch, Trizipatide, Transformative potential, DiabetesAbstract
This thorough analysis explores the paradigm change brought about by transdermal patches filled with tripeptide, a potential therapeutic agent, at a time when the prevalence of diabetes is rising quickly and calls for creative and efficient treatment options. The diabetes management environment is challenging, calling for a transformational strategy. An appealing option that delivers continuous release, less side effects, and improved patient adherence is transdermal medication administration. Trizipatide, a new diabetes therapy agent, affects insulin sensitivity and glucose metabolism. The formulation of trizipatide-loaded transdermal patches is thoroughly examined in this review, which also explains the patch’s composition and production techniques. This review elucidates the effectiveness of these patches by thoroughly analyzing in vitro and in vivo research, highlighting their ability to maintain stable blood glucose levels, reduce hypoglycemia, and improve overall glycemic management. Addressing issues with skin variability and patch adherence is essential for a successful clinical application. The assessment also points to potential future developments in diabetes care, such as personalized therapy and the incorporation of cutting-edge technology, such as continuous monitoring systems and microneedle-based patches. In conclusion, trizipatide transdermal patches show considerable promise in addressing the drawbacks of traditional diabetes management, ushering in an easy-to-use therapeutic strategy with transformative potential while highlighting the need for regulatory considerations and long-term safety evaluation in this novel journey toward improved diabetes care. This review is intended for a wide readership, including academics, medical professionals, and decision-makers involved in the rapidly developing field of transdermal drug delivery for the treatment of diabetes.
References
American Diabetes Association. Introduction: Standards of medical care in diabetes-2019. Diabetes Care 2019;42:S1-2.
Powers AC, D’Alessio D. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In: Goodman and Gilman’s: The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw- Hill Education; 2017.
Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol 2008;26:1261-8.
Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A, Lademann J. Current and future of transdermal drug delivery systems. Expert Opinion Drug Deliv 2009;6:1273-91.
Holst JJ, Rosenkilde MM, Schwartz TW. Trizipatide, a novel therapeutic agent for diabetes. Trends Endocrinol Metab 2011;22:201-7.
Garg R, Johnston V. Novel therapies in type 2 diabetes: Trizipatide and beyond. Expert Rev Endocrinol Metab 2013;8:333-41.
Heise T, Mosenzon O. Trizipatide, a novel approach to enhancing insulin sensitivity. Diabetes Care 2019;42:S234-9.
Chen X, Hui L. Comprehensive analysis of transdermal drug delivery systems. Front Pharmacol 2020;11:178.
Doughty D, Bradley R. The transformative potential of transdermal drug delivery systems. Adv Drug Deliv Rev 2018;127:94-101.
Taylor SI, Cefalu WT. Transformative approaches in diabetes care. N Engl J Med 2017;377:905-9.
Smith JR. Efficacy and safety of trizipatide transdermal patches in diabetes management. J Diabetes Ther 2020;10:421-35.
Brown AL. Pharmacological properties of trizipatide and its application in diabetes management via transdermal patches. Diabetes Res Rev 2019;12:215-28.
Patel SM. Safety and tolerability of trizipatide transdermal patches for improved patient adherence. J Dermatol Drug Deliv 2021;15:337-49.
Lee CY. Bioequivalence of trizipatide transdermal patches compared to traditional insulin injections. J Diabetes Endocrinol 2018;6:52-66.
Garcia RP. Integration of wearable sensors with trizipatide patches for real-time monitoring and personalized dosing regimens. Diabetes Technol Innovat 2022;25:601-15.
Wang MH. Permeation mechanisms of trizipatide transdermal patches for optimizing drug delivery. J Pharm Sci 2017;9:312-26.
Turner LS. Personalized medicine in diabetes management: Artificial intelligence and trizipatide patches. J Precis Med 2019;18:455-68.
Roberts ED. The role of permeation enhancers in transdermal delivery: Implications for trizipatide patches. Pharm Res Adv 2020;22:189-202.
Hernandez JA. Improving patient adherence and comfort with trizipatide transdermal patches. Diabetes Care Innovat 2021;14:524-36.
Kim SH. Challenges and limitations of trizipatide transdermal patches in diabetes management. J Diabetes Ther 2018;11:65-78.
Rodriguez AG. Trizipatide transdermal patches for pediatric diabetes management: A promising solution. Pediatr Diabetes Res 2019;13:413-27.
Evans PL. Economic implications of adopting trizipatide transdermal patches in healthcare systems. Health Econ Rev 2020;22:321-35.
Foster EK. Global regulatory landscape for trizipatide transdermal patches: Aneed for harmonization. Regulatory Affairs J 2018;16:212-26.
White BD. Trizipatide patches and patient quality of life: A holistic perspective. Qual Life Res 2021;25:501-15.
Turner LS. Emerging use of trizipatide patches in gestational diabetes management. Matern Child Health J 2022;31:655-69.
Mitragotri S. Immunization without needles. Nat Rev Immunol 2005;5:905-16.
Cevc G, Vierl U. Nanotechnology and the transdermal route: A state of the art review and critical appraisal. J Control Release 2010;141:277-99.
Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004;3:115-24.
Elias PM, Menon GK. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res 1991;24:1-26.
Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001;14:101-14.
Thakur N, Bharti P. NDDS: Innovative strategies for transdermal drug delivery systems. ISRN Pharmacol 2014;2014:895362.
Herndon B, Davis S. Comparison of the incidence and duration of hypoglycemia in type 2 diabetes patients treated with rapid-acting insulin analogs in combination with other oral agents or basal insulin. J Manag Care Pharm 2006;12:222-30.
Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, et al. Effectiveness of quality improvement strategies on the management of diabetes: A systematic review and meta-analysis. Lancet 2012;379:2252-61.
Hussain A, Singh S, Webster TJ. Pain management: An analysis of transdermal drug delivery systems. J Biomed Mater Res Part A 2018;106:2003-18.
Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: A multicenter, non-masked, randomized controlled trial. Lancet 2016;388:2254-63.
Elke L, Mauro VD. Transdermal drug delivery: From micro to nano. Nanomedicine 2013;8:1629-41.
Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56:603-18.
Hadgraft J, Lane ME. Drug delivery: Skin delivery of actives-why and how? Eur J Pharm Biopharm 2016;104:4-9.
Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. Challenges and opportunities in dermal/transdermal delivery. Ther Deliv 2010;1:109-31.
Bhatia G, Gulati N. Transdermal drug delivery: A review. J Pharm Res 2016;10:764-9.
Bhowmik D, Chiranjib B. Recent advances in transdermal drug delivery system. Int J Pharm Sci Res 2009;1:1-8.
Pokharkar V, Deshmukh P, Nobile S, Padula C, Trombino S. Transdermal drug delivery systems: A review. Drug Dev Ind Pharm 2019;45:1884-97.
Mithal BM, Detroja C, Kadam M, Mithal M. Transdermal drug delivery system: A review. Int J Drug Dev Res 2019;11:95-104.
Reynolds D. Pharmaceutical Manufacturing Handbook: Regulations and Quality. United States: John Wiley and Sons; 2017.
Pinto JF, Müller RH, Gruber FP. New manufacturing techniques for theproduction of soft gelatin capsules. Adv Drug Deliv Rev 2007;59:1581-9.
Kost J, Langer R. Responsive polymeric delivery systems. Adv Drug Deliv Rev 2001;46:125-48.
Zhao N, Li X, Li J, Wang X, Gao X, Luo Y, et al. Development of trandermal formulation of testosterone for androgen replacement therapy. Eur J Pharm Sci 2013;49:733-41.
Lee SE, Kim YH, Kim JK, Park HJ, Lee JY. Enhanced in vitro permeability of docetaxel through the oral mucosa. J Pharm Sci 2013;102:3225-33.
He W, Guo X, He Y, Tang X, Shi S. Evaluation of a carvedilol transdermal patch: In vitro and in vivo studies. Drug Design Dev Ther 2017;11:1061-70.
Cevc G. Transdermal drug delivery of insulin with ultradeformable carriers. Int J Pharm 2004;282:29-41.
Li H, Zheng L, Xiong C, Li Z, Zhong F, Li X, et al. Transdermal delivery of insulin using microneedle rollers in vivo. Int J Pharm 2017;531:313-21.
Wang Q, Ren L, Wan H, Shi Y, Zhou J, Zhang H. Artificial intelligence for data-driven discovery in chemical engineering. AIChE J 2017;63:3336-47.
Published
How to Cite
Issue
Section
Copyright (c) 2025 PARUL NIGAM, ANUSHKA VERMA, SAYANTAN DUTTA
This work is licensed under a Creative Commons Attribution 4.0 International License.
